Lead

The US Supreme Court has temporarily restored access to the abortion pill mifepristone, blocking a lower court ruling that would have significantly curtailed its availability by mail and telemedicine nationwide. The decision, announced on Thursday, came in response to emergency appeals from two manufacturers of the drug, Danco Laboratories and GenBioPro, and halts restrictions that had been set to take effect following a Fifth Circuit Court of Appeals ruling earlier this month.

Coverage Comparison

Coverage of the decision across outlets was broadly consistent, though the framing varied. Al Jazeera described the action as "temporarily reinstating" a rule allowing telemedicine prescriptions and mail dispensing, while The Guardian and the South China Morning Post emphasized that the court "restored broad access" to mifepristone, blocking a ruling that threatened "one of the main ways abortion is provided across the nation." BBC reports referred to the court "ruling that the abortion pill can continue to be accessed by mail," and The Intercept highlighted the dissents from Justices Clarence Thomas and Samuel Alito.

Most outlets noted that the court's decision was procedural, issued without detailed reasoning as part of its emergency docket. The Guardian specified that the court found Louisiana lacked standing, while Al Jazeera described the action as an "administrative stay" granting justices more time to review the manufacturers' requests. The BBC noted that access to the pill would likely remain unchanged until the underlying lawsuit is decided, possibly next year.

Key Claims

  • The Supreme Court’s order blocks restrictions on mail-order and telemedicine access to mifepristone while litigation continues.
  • The decision was a 7-2 ruling, with Justices Clarence Thomas and Samuel Alito dissenting.
  • Louisiana sued the FDA in October, arguing that nationwide mailing of mifepristone interfered with the state's abortion ban.
  • The Fifth Circuit had ruled in Louisiana's favor on 1 May, effectively banning mail-order mifepristone nationwide.
  • Mifepristone, often used with misoprostol, accounts for approximately two-thirds of abortions in the US and is the most common method of terminating pregnancies.
  • The FDA lifted the in-person dispensing requirement for mifepristone in 2021 during the COVID-19 pandemic and made that change permanent in 2023.
  • In his dissent, Justice Thomas argued that the Comstock Act of 1873 prohibits mailing abortion medication.

Perspectives

The court's decision was met with relief from abortion rights advocates, who said the immediate threat to mifepristone access had passed. Claire Teylouni, interim co-executive director of Reproductive Equity Now, told The Intercept: "We’re breathing a sigh of relief... But it’s certainly clear from reading those dissents that the threat... is far from over."

Conservative opponents of abortion, including Justices Thomas and Alito, expressed strong objections. Alito called the telemedicine access to mifepristone a "scheme" to circumvent the court's 2022 Dobbs decision, which removed the federal right to abortion. Thomas wrote that mailing mifepristone constitutes a "criminal enterprise" under the Comstock Act, an 1873 anti-obscenity law that prohibits mailing items intended for abortion.

Experts cited in The Guardian noted that years of research show abortion medications are safe and effective, with the combination regimen carrying a less than 1% risk of serious adverse events. They characterized recent legal challenges as "based on politics rather than evidence." The Intercept reported that in 2025, more residents of states with total abortion bans received telehealth provisions of medication abortion than traveled out of state for care.

The case is expected to return to the Supreme Court on a formal appeal, rather than emergency request, in a future term. The court's temporary stay is set to expire in the coming days, though justices may extend it or issue a further ruling.